



(86) Date de dépôt PCT/PCT Filing Date: 1999/07/20
(87) Date publication PCT/PCT Publication Date: 2000/02/03
(45) Date de délivrance/Issue Date: 2005/12/27
(85) Entrée phase nationale/National Entry: 2001/01/15
(86) N° demande PCT/PCT Application No.: ES 1999/000230
(87) N° publication PCT/PCT Publication No.: 2000/004881
(30) Priorité/Priority: 1998/07/21 (P 9801539) ES

(51) Cl.Int.⁷/Int.Cl.⁷ A61K 31/496, A61K 47/38, A61K 9/30,
A61K 9/16, A61P 31/10
(72) Inventeur/Inventor:
PICORNELL DARDER, CARLOS, ES
(73) Propriétaire/Owner:
LICONSA, LIBERACION CONTROLADA DE
SUSTANCIAS ACTIVAS, S.A., ES
(74) Agent: ROBIC

(54) Titre : PREPARATION PHARMACEUTIQUE ORALE D'UN COMPOSE A ACTIVITE ANTIFONGIQUE ET SON
PROCEDE DE PREPARATION
(54) Title: PHARMACEUTICAL ORAL PREPARATION OF A COMPOUND HAVING AN ANTIFUNGIC ACTIVITY, AND
PREPARATION METHOD

(57) **Abrégé/Abstract:**

Pharmaceutical preparation comprising a compound having an antifungic activity as active principle, an inert core and a coat which includes said active principle, and is characterized in that said inert core has a particle size between 50 and 600 µm, and is also characterized in that said coat has a unique layer which is produced by nebulization, on said inert core, of a solution which comprises a compound having an antifungic activity, a hydrophilic polymer and a non ionic surfactant. The method is carried out by means of a coating which comprises a unique layer of the inert cores having a size comprised between 50 and 600 µm by nebulization of a solution comprised of the antifungic agent, the hydrophilic polymer and the non ionic surfactant at constant coating speed throughout the process; a single drying process of the coat is required with the same equipment.





PCT ORGANIZACION MUNDIAL DE LA PROPIEDAD INTELECTUAL
Oficina Internacional
**SOLICITUD INTERNACIONAL PUBLICADA EN VIRTUD DEL TRATADO DE COOPERACION
EN MATERIA DE PATENTES (PCT)**

(51) Clasificación Internacional de Patentes ⁷ : A61K 9/16	A1	(11) Número de publicación internacional: WO 00/04881 (43) Fecha de publicación internacional: 3 de Febrero de 2000 (03.02.00)		
<table style="width: 100%; border: none;"> <tr> <td style="width: 50%; vertical-align: top; padding: 5px;"> (21) Solicitud internacional: PCT/ES99/00230 (22) Fecha de la presentación internacional: 20 de Julio de 1999 (20.07.99) (30) Datos relativos a la prioridad: P 9801539 21 de Julio de 1998 (21.07.98) ES (71) Solicitante (para todos los Estados designados salvo US): LI-CONSA, LIBERACION CONTROLADA DE SUSTANCIAS ACTIVAS, S.A. [ES/ES]; Calle Caleruega, 102, 6ª izq., E-28033 Madrid (ES). (72) Inventor; e (75) Inventor/solicitante (sólo US): PICORNELL DARDER, Carlos [ES/ES]; Calle Marcenado, 44, E-28002 Madrid (ES). (74) Mandatarios: PONTI SALES, Adelaida etc.; Calle Consell de Cent, 322, E-08007 Barcelona (ES). </td> <td style="width: 50%; vertical-align: top; padding: 5px;"> (81) Estados designados: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, Patente ARIPO (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Patente euroasiática (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), Patente europea (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), Patente OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Publicada <i>Con informe de búsqueda internacional.</i> </td> </tr> </table>			(21) Solicitud internacional: PCT/ES99/00230 (22) Fecha de la presentación internacional: 20 de Julio de 1999 (20.07.99) (30) Datos relativos a la prioridad: P 9801539 21 de Julio de 1998 (21.07.98) ES (71) Solicitante (para todos los Estados designados salvo US): LI-CONSA, LIBERACION CONTROLADA DE SUSTANCIAS ACTIVAS, S.A. [ES/ES]; Calle Caleruega, 102, 6ª izq., E-28033 Madrid (ES). (72) Inventor; e (75) Inventor/solicitante (sólo US): PICORNELL DARDER, Carlos [ES/ES]; Calle Marcenado, 44, E-28002 Madrid (ES). (74) Mandatarios: PONTI SALES, Adelaida etc.; Calle Consell de Cent, 322, E-08007 Barcelona (ES).	(81) Estados designados: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, Patente ARIPO (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Patente euroasiática (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), Patente europea (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), Patente OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Publicada <i>Con informe de búsqueda internacional.</i>
(21) Solicitud internacional: PCT/ES99/00230 (22) Fecha de la presentación internacional: 20 de Julio de 1999 (20.07.99) (30) Datos relativos a la prioridad: P 9801539 21 de Julio de 1998 (21.07.98) ES (71) Solicitante (para todos los Estados designados salvo US): LI-CONSA, LIBERACION CONTROLADA DE SUSTANCIAS ACTIVAS, S.A. [ES/ES]; Calle Caleruega, 102, 6ª izq., E-28033 Madrid (ES). (72) Inventor; e (75) Inventor/solicitante (sólo US): PICORNELL DARDER, Carlos [ES/ES]; Calle Marcenado, 44, E-28002 Madrid (ES). (74) Mandatarios: PONTI SALES, Adelaida etc.; Calle Consell de Cent, 322, E-08007 Barcelona (ES).	(81) Estados designados: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, Patente ARIPO (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Patente euroasiática (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), Patente europea (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), Patente OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Publicada <i>Con informe de búsqueda internacional.</i>			
(54) Title: PHARMACEUTICAL ORAL PREPARATION OF A COMPOUND HAVING AN ANTIFUNGIC ACTIVITY, AND PREPARATION METHOD (54) Título: PREPARACION FARMACEUTICA ORAL DE UN COMPUESTO DE ACTIVIDAD ANTIFUNGICA Y PROCEDIMIENTO PARA SU PREPARACION (57) Abstract Pharmaceutical preparation comprising a compound having an antifungic activity as active principle, an inert core and a coat which includes said active principle, and is characterized in that said inert core has a particle size between 50 and 600 μm, and is also characterized in that said coat has a unique layer which is produced by nebulization, on said inert core, of a solution which comprises a compound having an antifungic activity, a hydrophilic polymer and a non ionic surfactant. The method is carried out by means of a coating which comprises a unique layer of the inert cores having a size comprised between 50 and 600 μm by nebulization of a solution comprised of the antifungic agent, the hydrophilic polymer and the non ionic surfactant at constant coating speed throughout the process; a single drying process of the coat is required with the same equipment.				
(57) Resumen Comprende un compuesto de actividad antifúngica como principio activo, un núcleo inerte y un recubrimiento que incluye dicho principio activo, y se caracteriza por el hecho de que dicho núcleo inerte presenta un tamaño de partícula comprendido entre 50-600 μm, y por el hecho de que dicho recubrimiento comprende una única capa que se obtiene por nebulización, sobre dicho núcleo inerte, de una solución que comprende un compuesto de actividad antifúngica, un polímero hidrofílico y un agente tensioactivo no iónico. El procedimiento se lleva a cabo mediante un recubrimiento que comprende una única capa de los núcleos inertes de tamaño entre 50 y 600 μm por nebulización de una solución compuesta por el agente antifúngico, el polímero hidrofílico y el agente tensioactivo no iónico a una velocidad de recubrimiento constante durante todo el proceso; y un solo secado de dicho recubrimiento en el mismo equipo.				

PHARMACEUTICAL ORAL PREPARATION OF A COMPOUND HAVING AN
ANTIFUNGIC ACTIVITY, AND PREPARATION METHOD

Field of the invention

10 The present invention relates to an oral pharmaceutical composition comprising a compound having antifungal activity and in which the problems of low bioavailability, due to the poor solubility of antifungal compounds in an aqueous medium, are solved.

 The present invention also relates to a method for obtaining said oral pharmaceutical composition that has advantages over conventional methods.

Background of the invention

20 The problems of solubility associated to the chemical structures of azoles such as itraconazole and saperconazole, compounds respectively described in US patents 4,267,179 and 4,916,134, try to be solved by preparing different pharmaceutical forms on the base of the different administration methods.

 It is known that the solubility of a compound can increase when it is added to an hydrophilic polymer and apply the mixture on an inert core. A formulation is obtained that improves remarkably the bioavailability of the compound.

30 In patent EP 658103 (published in Spain as ES 2097536 T3) pellets of itraconazole and saperconazole prepared on the basis of this technology. It discloses the preparation of a solution in ethanol and methylene chloride of the antifungal compound and the hydrophilic polymer hydroxypropylmethylcellulose (HPMC) which is

sprayed in a fluidized bed on inert cores having a size between 600 and 700 μm . Once the spraying process is finished, the beads are dried in the same apparatus during ten minutes at a temperature of 50-55°C, but thereafter 5 they must be introduced in a vacuum drier for about 36 hours at a temperature of 80°C. The dry cores are sieved and are subjected to a second coating process in order to form a second layer with a solution of polyethylene glycol 20000 (PEG 20000) in a fluidized bed. When the process is 10 finished, the beads are dried in the apparatus for 10 minutes at 50-55°C and then dry air at 20-25°C is supplied to them during 5-15 minutes. When the drying process is finished, they are stored in suitable containers.

EP 658103 teaches that the second coating layer 15 with PEG 20000, which is a sealing coating layer, is applied in order to prevent pellets from adhering, and that it is necessary to have inert cores of a size between 600 and 700 μm in order to avoid drying problems and pellet aggregation. According to EP 658103, inert cores 20 having a larger size involve a smaller specific surface, whereby the coating layers need to be very thick and thus difficult to dry, while if the inert core size is too small it gives rise to a thin coating layer, easy to dry but that can undergo agglomeration phenomena during the 25 coating step.

Description of the invention

The present invention provides an oral 30 pharmaceutical formulation and a working method that allow to solve the problems of solubility, drying and bioavailability of pellets of antifungal compounds.

The new formulation object of the present invention is characterized in that it consists of

spherical beads comprising an inert core coated with a single layer of active charge comprising an antifungal compound. The process of coating the inert cores is carried out by spraying a solution of antifungal compound.

5 The oral pharmaceutical composition of the present invention comprises:

a/ an inert core

b/ a soluble active layer obtained from a solution comprising:

- 10 - an active principle having antifungal activity
 - an hydrophilic polymer
 - a non-ionic surfactant.

The active principles having antifungal activity included in the scope of the present invention are
 15 itraconazole, $(\pm)$ -*cis*-4-[4-[4-[4-[[2-(2,4-dichlorophenyl)-2-(1*H*-1,2,4-triazol-1-yl-methyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-1-piperazinyl]phenyl]-2,4-dihydro -2-(1-methylpropyl)-3*H*-1,2,4-triazol-3-one, and saperconazole, $(\pm)$ -*cis*-4-[4-[4-[4-[[2-(2,4-difluorophenyl)-2-(1*H*-1,2,4-triazol-1-yl-methyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-1-piperazinyl]phenyl]-2,4-dihydro-2-(1-methylpropyl)-3*H*-1,2,4-triazol-3-one.
 20

The inert cores are neutral spherical microbeads which can have in their composition one or more of the
 25 following substances: sorbitol, mannitol, saccharose, starch, microcrystalline cellulose, lactose, glucose, trehalose, maltitol and fructose. Their size is comprised between 50-600 μm , preferably between 500-600 μm .

In the present invention, the solution to be
 30 sprayed on inert cores is formed by the active principle having antifungal activity, dissolved in a mixture of organic solvents formed by ethanol and methylene chloride, in which the hydrophilic polymer is dissolved, and a surfactant.

The hydrophilic polymer can be HPMC, hydroxypropylcellulose (HPC), polyvinyl pyrrolidone (PVP), methacrylates, etc. The weight to weight ratio (w/w) between the antifungal agent and the polymer is in the 5 range [(1:1) - (1:3)].

The non-ionic surfactant can be propylene glycol esters, glycerol esters, (mono-di-tri-) acetylated sorbitan, (mono, di-tri) acetylated saccharose, polyoxyethylene sorbitan esters of fatty acids, 10 polyoxyethylene alkyl ethers of fatty chain, polyoxyethylene-polyoxypropylene copolymers.. etc. The weight to weight ratio between the antifungal agent and the surfactant lies within the range [(1.5:1)-(29:1)].

Another object of the present invention is a 15 method for manufacturing the Galenic formulations of the invention.

In the following the method is described, paying special attention to the proportions of each component and the methodology used.

20 In a stainless steel tank of suitable size, ethanol and methylene chloride (65:35) (w/w) is mixed. The antifungal compound (2.8% - 5.0%) (w/w), the hydrophilic polymer (3.5% - 6.3%) (w/w) and the surfactant (0.2% - 2.0%) (w/w) are added.

25 Thereafter the coating solution is sprayed to obtain a single layer on the neutral pellets having a size comprised between 50 and 600 μm , preferably 500-600 μm , in a fluidized bed. During the whole process the spraying speed is constant and the temperature is maintained at 30 45°C.

When the coating step is finished, the pellets are kept in the apparatus for 15 minutes at a temperature of 45°C, this being the last drying step.

This technology allows to work with inert cores

of a size between 50 and 600 μm , which is smaller than that claimed in EP 658103 and which favours the coating process due to the increase of specific surface; surprisingly, this size does not give rise to any
5 agglomeration problem, and further the layer of PEG 20000 sealing coating is not necessary, because the incorporation of the non-ionic surfactant surprisingly prevents particle agglomeration.

With the present invention the cost of the
10 process is reduced by a reduction in time and in use of the apparatus, and at the same time the final drying of the beads is favoured, thus minimizing the risk of non fulfilment of the Proper Manufacturing Standards.

The present invention uses a fluidized bed in
15 which the coating process is carried out. It is not necessary to use a second apparatus to dry the coated beads: on the contrary, a short drying step (15 minutes at 45°C), carried out in the same apparatus after completing the coating step of the single layer, is sufficient. Thus
20 not only is the processing time lowered with respect to that of EP 658103, because the pellets or beads do not need to be placed in a vacuum drier: at the same time the step of subjecting them to extreme temperatures of 80°C during 36 hours is avoided.

25 During the spraying process, the temperature to which the cores are subjected is 45°C, lower than the working temperature in EP 658103, and this is also a positive factor for controlling the chemical stability of the active principle and for avoiding the drawback,
30 already commented in EP 658103, that high temperatures may accelerate drying of the beads, with the risk of formation of layers that are non-uniform and have high porosity.

During the coating process, the spraying speed is a factor to be considered in order to obtain a higher

efficiency in the process. In EP 658103 it is recommended to start with a low speed that is gradually increased along the process; it is even mentioned that a speed too high can cause an excessive moistening of the beads, 5 resulting in agglomeration phenomena. On the contrary, if the speed is low product losses can occur due to drying of the spray itself. In EP 658103 the spraying speed at the beginning of the coating, for the obtention of the first layer, is about 600-700 g/min, and it is raised to 800 10 g/min once 30% of the coating solution has been consumed. This range of speeds is higher than those used in the present invention. The coating speed of the present invention is lower and is maintained constant throughout the whole process.

15 In the present invention the technology described in EP 658103 has been improved, since work is performed with inert cores of smaller size than those described in EP 658103, without causing agglomeration of the beads. On the other hand, spraying at lower speed is achieved with 20 no product losses, and the drying of the final beads is carried out at lower working temperatures and reducing the drying process practically to the loading time.

The use of a single apparatus in which both the coating step, comprising only one layer, and the drying, 25 allows for another advantage not only in cost but also in processing time, and this in its turn involves less handling of the final bead, with improvements of its chemical and physical integrity.

30 Example

18.60 kg of methylene chloride and 10.00 kg of ethanol are mixed in a stainless steel container; then 0.98 kg of itraconazole, 1.32 kg of

hydroxypropylmethylcellulose and 0.39 kg of poloxamer are introduced.

In the fluidized bed are introduced 2 kg of inert cores composed of saccharose (62.5%-91.5%) and starch 5 (37.5%-8.5%), having a size of 500-600 μm , and they are coated with the solution previously prepared, at a spraying speed of 30g/min and at a product temperature of 45°C. Once the coating step is finished, the charged cores are dried in the same apparatus during 15 minutes at 45°C.

WHAT IS CLAIMED IS:

1. An oral pharmaceutical composition in the form of a pellet, comprising a compound having antifungal activity as active principle selected between itraconazole and saperconazole, an inert core and a coating including said active principle, characterised in that said inert core has a particle size comprised between 50 and 600 μm and in that said coating comprises a single layer obtained by spraying, on said inert core, a solution comprising said compound having antifungal activity, a hydrophilic polymer and a non-ionic surfactant.
10
2. An oral pharmaceutical composition as claimed in claim 1, characterized in that said inert core has a particle size comprised between 500 and 600 μm .
3. An oral pharmaceutical composition as claimed in claim 1, characterized in that said hydrophilic polymer is selected among the group comprising hydroxypropylmethylcellulose (HPMC), hydroxypropylcellulose (HPC), polyvinyl pyrrolidone (PVP) and methacrylates.
4. An oral pharmaceutical composition as claimed in claim 1, characterized in that said non-ionic surfactant selected from propylene glycol esters, glycerol esters, monoacetylated sorbitan, diacetylated sorbitan, triacetylated sorbitan, monoacetylated saccharose, diacetylated saccharose, triacetylated saccharose, polyoxyethylene sorbitan esters of fatty acids, polyoxyethylene alkyl ethers of fatty chain, polyoxyethylene-polyoxypropylene copolymers.
20
5. An oral pharmaceutical composition as claimed in any one of claims 1 to 4, characterized in that the proportions of hydrophilic polymer, non-ionic surfactant, active principle and inert core in the final pellet are,

respectively: hydrophilic polymer (25%-60%), non-ionic surfactant (1%-15%), antifungal compound (10%-30%), and inert core (10%-45%).

6. The oral pharmaceutical composition according to claim 5, characterized in that the proportion of hydrophilic polymer is 27%-55%.

7. The oral pharmaceutical composition as claimed in claim 5, characterized in that the proportion of non-ionic surfactant is 3%-10%.

8. The oral pharmaceutical composition as claimed in claim 5, characterized in that the proportion of antifungal compound is 20%-25%.

9. The oral pharmaceutical composition as claimed in claim 5,
10 characterized in that the proportion of inert core is 15%-43%.

10. An oral pharmaceutical composition as claimed in any one of claims 1 to 9, characterized in that the weight to weight ratio between the antifungal compound and hydrophilic polymer is [(1:1)-(1:3)] and between the antifungal compound and the surfactant is [(1.5:1)-(29:1)].

11. A method for obtaining an oral pharmaceutical composition as claimed in any one of claims 1 to 11, characterized in that the following steps are performed in an apparatus:

- 20 a) a coating, comprising a single layer, of the inert cores having a size between 50 and 600 μm , by means of the spraying of a solution composed by the antifungal agent, the hydrophilic polymer and the non-ionic surfactant, at a constant coating speed throughout the whole process; and
- b) a single drying step of said coating in the same apparatus.